What a downhill trajectory …
Once upon a time, business had a
simple obsession with market share. The idea being that your product, or
service, or whatever it is you're selling, should aspire to have a high (and
higher!) percentage of the market share of business spending.
Almost twenty years ago, I
edited a Wall Street Journal story on what was a new phenomenon in my books:
stomach share.
In this instance, Coke marketers
were investigating research algorithms to track a consumer’s stomach share, as
in how much Coke was in an individual stomach, compared to other drinks and
food, and what time of day too. Coke float for breakfast?
Okay, now under Trump’s
deregulation regime, in which the FDA stands to be even less vigilant during
Obama’s rule, expect vomit share to have its day.
Conjecture: Can we trust drug
companies NOT to develop appetite suppression side effects to common medication
so that, well, if not outright nausea-producing, the drug bits of their
multibillion-dollar products show up in a greater and greater share of a
consumer vomit. (Appetite suppression being critical to keep folks from, well, consuming other things beyond their drug products.)
Point of fact: Plenty of healthy
food nutrients will treat most common ailments, but it’s not as though US
health authorities go to any lengths to draw that to our attention.
Why would you think they would
start to being concerned about consumers' total health and well-being now?
Truth is the “science” of drugs
in America promote the drugmakers. As is “elite science” when it comes to
debunking spiritualism, the topic of my next blog post, when Scientific
American magazine set out to find definable proof that there is such a thing as
ghosts …
Next: Running for Your Life: Through
a Glass, Darkly
0 comments:
Post a Comment